Our lead drug candidate, ACU193, is an immunotherapy designed to target toxic amyloid-beta oligomers (Aβo) - now widely recognized as primary triggers of Alzheimer’s.

We expect to initiate clinical trials for ACU193 in 2020 as the first monoclonal antibody that selectively targets Aβo in Alzheimer’s patients.